Several new risk factors have been identified and include a dysregulation of the immune system occurring during acute and chronic GVHD and their treatments, persistently reduced regenerating capacity of normal osteogenic cell compartment, and osteoclastic activation by alterations in the RANKL/OPG balance. This evidence concerns the gene TNFSF11 and graft versus host disease.